|
vitamin d |
38 |
|
atrial fibrillation |
31 |
|
25-hydroxyvitamin d |
23 |
|
ischemic stroke |
22 |
|
hypertension |
19 |
|
mendelian randomization |
19 |
|
myocardial infarction |
19 |
|
type 2 diabetes mellitus |
19 |
|
recurrence |
17 |
|
secondary prevention |
17 |
|
stroke |
16 |
|
endothelial progenitor cells |
15 |
|
chinese |
13 |
|
coronary artery disease |
13 |
|
nasopharyngeal carcinoma |
13 |
|
type 2 diabetes |
13 |
|
female |
12 |
|
humans |
12 |
|
male |
12 |
|
middle aged |
12 |
|
adverse outcome |
11 |
|
tricuspid annuloplasty |
11 |
|
trimetazidine |
11 |
|
blood pressure variability |
10 |
|
case-control study |
10 |
|
endothelial function |
10 |
|
epidemiology |
10 |
|
epstein-barr virus |
10 |
|
exome chip |
10 |
|
genetic polymorphism |
10 |
|
incidence |
10 |
|
medical sciences |
10 |
|
vascular function |
10 |
|
vitamin d-binding protein |
10 |
|
aged |
9 |
|
berberine |
9 |
|
carotid intima-media thickness |
9 |
|
diabetes mellitus |
9 |
|
dietary fiber |
9 |
|
fresh vegetable and fruit |
9 |
|
garlic |
9 |
|
genetic epidemiology |
9 |
|
genetic variant |
9 |
|
heart failure |
9 |
|
insulin resistance |
9 |
|
life-course |
9 |
|
milk |
9 |
|
mortality |
9 |
|
multiple imputation |
9 |
|
preserved food |
9 |
|
safety |
9 |
|
sex disparity |
9 |
|
soybean product |
9 |
|
ultraviolet radiation |
9 |
|
vitamin d deficiency |
9 |
|
young-onset ischemic stroke |
9 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
case-control studies |
8 |
|
cha2ds2-vasc |
8 |
|
chads2 |
8 |
|
cigarette smoking |
8 |
|
dietary supplements |
8 |
|
dose-response relation |
8 |
|
endothelial dysfunction |
8 |
|
follow-up studies |
8 |
|
high-sensitivity troponin i |
8 |
|
inflammation |
8 |
|
physical activity |
8 |
|
risk factors |
8 |
|
risk prediction |
8 |
|
smoking cessation |
8 |
|
thirdhand smoke |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
arthritisosteogenesis |
7 |
|
blood flow velocity |
7 |
|
blood pressure |
7 |
|
bone–vascular axis |
7 |
|
calcification |
7 |
|
cha2ds2-vasc score |
7 |
|
chads2 score |
7 |
|
circulating endothelial progenitor cells |
7 |
|
conduction disorders |
7 |
|
drug repositioning |
7 |
|
endothelial cells - pathology |
7 |
|
genome sequencing |
7 |
|
genomic diversity |
7 |
|
hong kong |
7 |
|
hong kong genome project |
7 |
|
ischemic heart disease |
7 |
|
isoflavone |
7 |
|
long read genome sequencing |
7 |
|
lung cancer |
7 |
|
metabolic re-programming |
7 |
|
osteocalcin |
7 |
|
osteogenic endothelial progenitor cells |
7 |
|
pleiotropic effects |
7 |
|
population-based genome project |
7 |
|
pr prolongation |
7 |
|
precision medicine |
7 |
|
questionnaires |
7 |
|
rare disease |
7 |
|
rheumatoid |
7 |
|
short read genome sequencing |
7 |
|
statin therapy |
7 |
|
stem cells - pathology |
7 |
|
treatment outcome |
7 |
|
adolescents |
6 |
|
adult |
6 |
|
adverse cardiovascular events |
6 |
|
adverse cardiovascular outcomes |
6 |
|
age |
6 |
|
age factors |
6 |
|
ankle brachial index |
6 |
|
antiplatelet agents |
6 |
|
arterial stiffiness |
6 |
|
arterial stiffness |
6 |
|
aspirin - administration & dosage - adverse effects |
6 |
|
atrial fibrillation - complications |
6 |
|
atrioventricular block - complications - diagnosis - physiopathology |
6 |
|
bleeding |
6 |
|
brachial artery - physiopathology |
6 |
|
brachial artery - physiopathology - ultrasonography |
6 |
|
brain ischemia - epidemiology - etiology |
6 |
|
cardiovascular continuum |
6 |
|
cardiovascular death |
6 |
|
cardiovascular diseases - blood - diet therapy - prevention & control |
6 |
|
cardiovascular diseases - etiology |
6 |
|
cardiovascular diseases - etiology - physiopathology |
6 |
|
chads2 and cha2ds2-vasc scores |
6 |
|
confounding factors (epidemiology) |
6 |
|
coronary artery calcium |
6 |
|
cross-sectional studies |
6 |
|
deficiency diseases - complications - physiopathology |
6 |
|
diet |
6 |
|
diet records |
6 |
|
drug interaction |
6 |
|
drug-target mendelian randomization |
6 |
|
electric countershock |
6 |
|
electrocardiography |
6 |
|
endothelial cells - cytology - physiology |
6 |
|
endothelium, vascular - cytology - physiology |
6 |
|
energy intake |
6 |
|
flow cytometry |
6 |
|
glycated hemoglobin a |
6 |
|
hip fractures |
6 |
|
hmgcr inhibitors |
6 |
|
hyperthyroidism |
6 |
|
hyperthyroidism - complications |
6 |
|
hypoglycemia |
6 |
|
infection |
6 |
|
influenza virus |
6 |
|
intracranial hemorrhages - drug therapy - physiopathology - surgery |
6 |
|
liver stiffness |
6 |
|
mediterranean-style diet |
6 |
|
myocardial injury |
6 |
|
nonvalvular atrial fibrillation |
6 |
|
non–vitamin k oral anticoagulant |
6 |
|
nutrition |
6 |
|
nutrition assessment |
6 |
|
osteoporosis |
6 |
|
pathophysiological mechanism |
6 |
|
pcsk9 inhibitors |
6 |
|
peripheral artery disease |
6 |
|
phytoestrogen |
6 |
|
phytoestrogens - administration & dosage |
6 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects |
6 |
|
postmenopause |
6 |
|
pr interval prolongation |
6 |
|
proportional hazards models |
6 |
|
prospective studies |
6 |
|
recurrent stroke |
6 |
|
registries |
6 |
|
retrospective studies |
6 |
|
risk |
6 |
|
selenium - administration & dosage - deficiency |
6 |
|
selenium deficiency |
6 |
|
serology |
6 |
|
solar radiation |
6 |
|
stem cells - physiology |
6 |
|
stroke/prevention |
6 |
|
trace elements - deficiency |
6 |
|
type 2 |
6 |
|
vascular diseases - etiology - physiopathology |
6 |
|
vascular dysfunction |
6 |
|
vasodilation |
6 |
|
antibiotics resistance |
5 |
|
antigens, cd34 - analysis |
5 |
|
arteriosclerosis - etiology - pathology - ultrasonography |
5 |
|
atrial fibrillation - pathology - therapy |
5 |
|
axial spondyloarthritis |
5 |
|
brachial artery - drug effects - physiology |
5 |
|
c-reactive protein |
5 |
|
c-reactive protein - metabolism |
5 |
|
cardiovascular diseases |
5 |
|
carotid arteries - pathology - ultrasonography |
5 |
|
cell count |
5 |
|
community |
5 |
|
diabetes mellitus, type 2 - pathology - physiopathology |
5 |
|
early detection |
5 |
|
education |
5 |
|
effective regurgitant orifice area (eroa) |
5 |
|
electrical cardioversion |
5 |
|
endothelial cells - cytology |
5 |
|
endothelium, vascular - drug effects |
5 |
|
endothelium, vascular - pathology - ultrastructure |
5 |
|
endothelium, vascular - physiopathology |
5 |
|
hematopoietic stem cells - cytology |
5 |
|
isoflavones - administration and dosage - therapeutic use |
5 |
|
knowledge |
5 |
|
left ventricular longitudinal strain |
5 |
|
left-sided valve disease |
5 |
|
major adverse cardiovascular events |
5 |
|
nonadherence |
5 |
|
prognostication |
5 |
|
randomized controlled trial |
5 |
|
rheumatic valvular heart disease |
5 |
|
soybean proteins - therapeutic use |
5 |
|
stroke - pathology |
5 |
|
testosterone |
5 |
|
treatment |
5 |
|
tricuspid regurgitation (tr) |
5 |
|
tunica intima - ultrasonography |
5 |
|
tunica media - ultrasonography |
5 |
|
vitamin d deficiency - pathology |
5 |
|
abc pathway |
4 |
|
adipokines |
4 |
|
af |
4 |
|
analysis of variance |
4 |
|
atrial fibrillation - etiology - therapy |
4 |
|
atrial high rate |
4 |
|
blood glucose |
4 |
|
blood pressure - drug effects - physiology |
4 |
|
brachial artery - pathology |
4 |
|
cardiovascular diseases - blood - diagnosis - mortality |
4 |
|
cardiovascular diseases - epidemiology - metabolism |
4 |
|
cardiovascular outcomes |
4 |
|
carotid arteries - pathology |
4 |
|
coronary artery disease - pathology |
4 |
|
cross-talk |
4 |
|
cryptogenic |
4 |
|
cytokines |
4 |
|
descriptive epidemiology |
4 |
|
diabetes mellitus, type 2 - blood - diagnosis - mortality |
4 |
|
diet surveys |
4 |
|
efficacy |
4 |
|
endothelium, vascular - drug effects - physiology |
4 |
|
environmental risk factors |
4 |
|
flow-mediated dilation |
4 |
|
hepatokines |
4 |
|
hf |
4 |
|
high-sensitivity troponin i outcome |
4 |
|
implantable cardioverter-defibrillater |
4 |
|
implanted pacemaker |
4 |
|
insertable cardiac monitor |
4 |
|
integrated care |
4 |
|
interleukins |
4 |
|
ischemia |
4 |
|
isoflavones - administration & dosage |
4 |
|
lipid metabolism - drug effects - physiology |
4 |
|
manufacturers |
4 |
|
masld |
4 |
|
metabolic reprogramming |
4 |
|
population screening |
4 |
|
post-stroke care |
4 |
|
sex-specific effect |
4 |
|
soybean proteins - administration & dosage |
4 |
|
soybeans - chemistry |
4 |
|
time factors |
4 |
|
troponin i - blood |
4 |
|
tunica intima - pathology |
4 |
|
tunica intima - pathology - ultrasonography |
4 |
|
tunica media - pathology - ultrasonography |
4 |
|
*food habits |
3 |
|
*vascular stiffness |
3 |
|
acute coronary syndrome |
3 |
|
anthracyclines |
3 |
|
atrial synchronous pacing |
3 |
|
calcium |
3 |
|
cardiac autonomic dysfunction |
3 |
|
cardio-oncology |
3 |
|
cardiorenal syndrome |
3 |
|
cardiovascular diseases/diagnosis/*etiology/physiopathology |
3 |
|
cardiovascular mortality |
3 |
|
charlson comorbidity index |
3 |
|
checklist |
3 |
|
china |
3 |
|
chronic kidney disease |
3 |
|
clinical care pathways |
3 |
|
dietary carbohydrates/*adverse effects |
3 |
|
dpp-4 inhibitors |
3 |
|
genome wide association analysis |
3 |
|
glycemic control |
3 |
|
high comorbidity burden |
3 |
|
hyperglycaemia |
3 |
|
hyperglycemia - drug therapy |
3 |
|
hyperkalaemia |
3 |
|
implementation research |
3 |
|
leadless pacemaker |
3 |
|
nutritional status |
3 |
|
older people |
3 |
|
pacing |
3 |
|
parathyroid hormone |
3 |
|
periodontal diseases |
3 |
|
pr interval |
3 |
|
prediabetes |
3 |
|
pulse wave analysis |
3 |
|
resting heart rate |
3 |
|
sglt2 inhibitors |
3 |
|
smoking |
3 |
|
treatment inertia |
3 |
|
vascular disease vitamin d |
3 |
|
vdd |
3 |
|
vitamin d - analogs and derivatives - blood - therapeutic use |
3 |
|
vitamins - blood - therapeutic use |
3 |
|
vvi |
3 |
|
alcohol |
2 |
|
aspirin - administration and dosage |
2 |
|
blood-vessels. |
2 |
|
cardiovascular diseases - epidemiology |
2 |
|
catheter ablation |
2 |
|
colorectal neoplasms - diagnosis - epidemiology - prevention and control |
2 |
|
echocardiography |
2 |
|
gastrointestinal hemorrhage - chemically induced |
2 |
|
high-frequency low-tidal volume ventilation |
2 |
|
human papillomavirus |
2 |
|
left ventricular hypertrophy |
2 |
|
nasopharyngeal cancer |
2 |
|
pathway analysis |
2 |
|
phytoestrogens. |
2 |
|
platelet aggregation inhibitors - administration and dosage |
2 |
|
pulmonary vascular resistance |
2 |
|
subtype |
2 |
|
tricuspid regurgitation |
2 |
|
vertical transmission |
2 |
|
cardiovascular disease |
1 |
|
editorials |
1 |
|
pregnancy |
1 |
|
women |
1 |
